Lind, M., Gettinger, S., Borghaei, H., Brahmer, J., Chow, L., Burgio, M., De Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O. A., Chiari, R., Butts, C., Wojcik-Tomaszewska, J., Coudert, B., Garassino, M., Ready, N., Felip, E., Garcia, M. A., Waterhouse, D., Domine, M., Barlesi, F., Antonia, S., Wohlleber, M., Gerber, D., Czyzewicz, G., Spigel, D., Crino, L., Eberhardt, W., Li, A., Marimuthu, S., & Vokes, E. (n.d.). five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Lung cancer, 139, S49–S50. http://access.bl.uk/ark:/81055/vdc_100099354041.0x00004d